JPH11170A - デスドメイン含有受容体 - Google Patents

デスドメイン含有受容体

Info

Publication number
JPH11170A
JPH11170A JP9057503A JP5750397A JPH11170A JP H11170 A JPH11170 A JP H11170A JP 9057503 A JP9057503 A JP 9057503A JP 5750397 A JP5750397 A JP 5750397A JP H11170 A JPH11170 A JP H11170A
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
seq
nucleotide sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9057503A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11170A5 (https=
Inventor
Guo-Liang Yu
グオ−リェン・ユ
Jian Ni
ジェン・ニ
Vishva Dixit
ビシュバ・ディキシット
Reiner L Gentz
レイナー・エル・ジェンツ
Patrick J Dillon
パトリック・ジェイ・ディロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
University of Michigan Ann Arbor
Original Assignee
Human Genome Sciences Inc
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, University of Michigan Ann Arbor filed Critical Human Genome Sciences Inc
Publication of JPH11170A publication Critical patent/JPH11170A/ja
Publication of JPH11170A5 publication Critical patent/JPH11170A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP9057503A 1996-03-12 1997-03-12 デスドメイン含有受容体 Pending JPH11170A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1328596P 1996-03-12 1996-03-12
US2871196P 1996-10-17 1996-10-17
US3734197P 1997-02-06 1997-02-06
US60/013285 1997-02-06
US60/028711 1997-02-06
US60/037341 1997-02-06

Publications (2)

Publication Number Publication Date
JPH11170A true JPH11170A (ja) 1999-01-06
JPH11170A5 JPH11170A5 (https=) 2005-02-10

Family

ID=27359824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9057503A Pending JPH11170A (ja) 1996-03-12 1997-03-12 デスドメイン含有受容体

Country Status (3)

Country Link
US (3) US6153402A (https=)
JP (1) JPH11170A (https=)
WO (1) WO1997033904A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025018311A1 (ja) 2023-07-14 2025-01-23 旭化成株式会社 金属複合材料

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
JP2000506743A (ja) * 1996-10-04 2000-06-06 イミュネックス・コーポレーション 細胞死を引き起こす新規受容体
US6297022B1 (en) 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
CA2321105A1 (en) * 1998-02-17 1999-08-19 Incyte Pharmaceuticals, Inc. Human short-chain tnf-receptor family protein
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP1178815A4 (en) * 1999-04-22 2003-02-05 Human Genome Sciences Inc THE "DEATH DOMAIN" RECEPTORS
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
EP1231937A2 (en) * 1999-11-19 2002-08-21 Thomas V. Tittle Tr3-specific binding agents and methods for their use
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2002210926B2 (en) 2000-10-24 2005-12-15 Shunichi Shiozawa Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis
US6965023B2 (en) * 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005018571A2 (en) * 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
CN102227503B (zh) 2008-09-26 2015-10-21 托卡根公司 重组载体
SG10201502330TA (en) 2009-08-03 2015-05-28 Univ Miami Method for in vivo expansion of t regulatory cells
SG191716A1 (en) 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
BR112013022052A2 (pt) 2011-03-01 2016-11-22 Novo Nordisk As ligantes antagonísticos de dr3
WO2012161856A1 (en) * 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
ES2786051T3 (es) 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor
US20140193410A1 (en) 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0103960B1 (en) * 1982-07-30 1991-01-23 Mach, Bernard François, Prof. Dna sequences coding for the dr beta-chain locus of the human lymphocyte antigen complex and polypeptides, diagnostic typing processes and products related thereto
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
IL106271A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5464938A (en) * 1990-04-09 1995-11-07 Immunex Corporation Isolated viral protein TNF antagonists
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP0506477B1 (en) 1991-03-28 1999-06-23 Merck & Co. Inc. Vascular endothelial cell growth factor C subunit
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1994009137A1 (en) * 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
CA2150249A1 (en) * 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
WO1995010540A1 (en) 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
JP4046349B2 (ja) 1994-11-07 2008-02-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子−γ
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
JPH11507205A (ja) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
CA2249206A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
WO1998002543A1 (fr) 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf
ATE412740T1 (de) 1996-08-16 2008-11-15 Human Genome Sciences Inc Menschliches alpha-endokin
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
EP1283268A3 (en) 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor D (VEGF-D)
JP2000506743A (ja) * 1996-10-04 2000-06-06 イミュネックス・コーポレーション 細胞死を引き起こす新規受容体
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
JP2001505060A (ja) 1997-01-14 2001-04-17 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 腫瘍壊死因子受容体 ５
CA2277925A1 (en) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
JP4330180B2 (ja) 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
CA2288351A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
CA2295991A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025018311A1 (ja) 2023-07-14 2025-01-23 旭化成株式会社 金属複合材料

Also Published As

Publication number Publication date
US6153402A (en) 2000-11-28
US20020009773A1 (en) 2002-01-24
US6951735B2 (en) 2005-10-04
US6759513B2 (en) 2004-07-06
WO1997033904A1 (en) 1997-09-18
US20030077694A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
US6759513B2 (en) Death domain containing receptors
JP4450870B2 (ja) 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
JP4330180B2 (ja) 死ドメイン含有レセプター５
US6261801B1 (en) Nucleic acids encoding tumor necrosis factor receptor 5
JP2001507937A (ja) 腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β
JP2002511070A (ja) ヒト腫瘍壊死因子受容体ｔｒ１０
JP2002503963A (ja) ヒト腫瘍壊死因子受容体ｔｒ９
EP1788086A1 (en) Death Domain Containing Receptor 5
EP0898576A1 (en) Death domain containing receptors
MXPA99008486A (en) Death domain containing receptor 5
HK1025352B (en) Death domain containing receptor 5
AU2006246525A1 (en) Death Domain Containing Receptor 5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060920

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070306